Global Conjugated Monoclonal Antibodies Markets, 2020-2030: COVID-19 Growth, Impacts and Changes
22 déc. 2020 06h08 HE
|
Research and Markets
Dublin, Dec. 22, 2020 (GLOBE NEWSWIRE) -- The "Conjugated Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. ...
Global Protein Therapeutics Market Assessment 2020-2025 - Outbreak of COVID-19 Providing Growth Opportunities, Development of Novel Recombinant Proteins Driving Growth
16 nov. 2020 13h48 HE
|
Research and Markets
Dublin, Nov. 16, 2020 (GLOBE NEWSWIRE) -- The "Protein Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to...
Protein Therapeutics Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2012–2022
20 nov. 2017 01h10 HE
|
Crystal Market Research
LAS VEGAS, Nov. 20, 2017 (GLOBE NEWSWIRE) -- The Protein Therapeutics Market was worth USD 123.54 billion in the year of 2012 and is expected to reach approximately USD 241 billion by 2022, while...
iBio Receives US and European Patents for Protein Expression Technology
12 févr. 2015 08h31 HE
|
iBio, Inc.
NEWARK, DE--(Marketwired - Feb 12, 2015) - iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, today announced the issuance of...
iBio Adds to iBioModulator Portfolio and Product Pipeline
04 févr. 2015 08h31 HE
|
iBio, Inc.
NEWARK, DE--(Marketwired - Feb 4, 2015) - iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, today announced the issue of a new...
iBio Provides Updates on Its IBIO-CFB03 Fibrosis Drug Candidate and Other Activities for the 2014 Annual Shareholders Meeting
10 déc. 2014 08h31 HE
|
iBio, Inc.
NEWARK, DE--(Marketwired - Dec 10, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leader in biotechnology for developing and manufacturing plant-made pharmaceutical products, will provide shareholders and...
iBio Grants Caliber License for Production of Antibodies Targeting Ebola
10 nov. 2014 08h31 HE
|
iBio, Inc.
NEWARK, DE--(Marketwired - Nov 10, 2014) - iBio, Inc. (NYSE MKT: IBIO) and Caliber Biotherapeutics LLC executed an agreement, effective today, for an emergency use license to the iBioLaunch™...
iBio Expands Exclusive Product Collaboration With Novici Biotech
22 oct. 2014 08h31 HE
|
iBio, Inc.
NEWARK, DE--(Marketwired - Oct 22, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, and Novici Biotech LLC...
iBio Responds to Inquiries About its Role in Emergency Response to Ebola Virus Disease Outbreak
16 oct. 2014 08h31 HE
|
iBio, Inc.
NEWARK, DE--(Marketwired - Oct 16, 2014) - iBio, Inc. (NYSE MKT: IBIO) today confirmed, in response to shareholder and media inquiries: (i) the applicability of its issued U.S. iBioLaunch™...
iBio Reports on Filing of 2014 Annual Report
03 oct. 2014 17h00 HE
|
iBio, Inc.
NEWARK, DE--(Marketwired - Oct 3, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced, as required...